# Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $751,170

## Abstract

Project Summary
African American (AA) women experience higher rates of breast cancer mortality, even when accounting for
confounding clinical and sociodemographic factors. This disparity reflects in part the fact that AA women in the
US are approximately twice as likely as Caucasian (CA) women to develop Triple-Negative Breast Cancer
(TNBC), a particularly aggressive breast cancer subset. However, even among those with TNBC, AA race is
independently associated with inferior treatment responses and poorer survival rates. These and other data
including our own work have led to an emerging consensus that that this excess mortality is due in part to
biological differences between TNBCs in AA versus CA women. For example, recent genomic analyses have
demonstrated distinct somatic mutation profiles in TNBCs among AA women. Our recent analysis of gene
expression subtypes of TNBC by race showed that the increase in disease progression among AA women was
selective for the intrinsic basal TNBC subset. In a separate study, we and collaborators demonstrated distinct
mechanisms of homologous recombination (HR) deficiency in TNBCs from AA versus CA women. Finally, we
also discovered that inferred subclonal heterogeneity, a measure reflecting malignant cell sub-populations
within the tumor that is known to be associated with poor clinical outcomes in TNBC, in significantly higher in
TNBCs of AA compared to CA women. This finding may explain why bulk tumor analysis has largely failed to
provide mechanistic or actionable insights into the biological differences in TNBC between AA and CA women.
Collectively, these findings support the hypothesis that distinct tumor characteristics including increased
subclonal heterogeneity contribute to poorer clinical outcomes for AA women with TNBC. These results
warrant a focused and detailed investigation of TNBC biology in AA women. Accordingly, we have initiated a
coordinated, innovative and highly synergistic inter-institution collaboration, bringing together leading
investigators with complementary expertise, employing state-of-the-art methodologies to address this unmet
need. We propose genomic, epigenetic and gene expression profiling including single-cell analysis in TNBCs
among AA and other women in order to reveal drivers that explain poorer outcomes in the AA population and
discover new, therapeutically actionable means of intervening. We will Identify driver pathways and cell
subpopulations that correlate with primary response to neoadjuvant chemotherapy among AA vs. CA women
with TNBC. We will then examine clonal selection and discover resistant sub-populations through pre/post
neoadjuvant chemotherapy analysis of TNBC in AA women. Next, we will determine the prevalence by race of
genomic/epigenetic alterations and cell subpopulations and their ability to predict long-term outcomes through
retrospective TNBC cohort analysis. Finally, we will establish ex vivo and PDX models of primary TNBC for
specific mechanistic...

## Key facts

- **NIH application ID:** 10347682
- **Project number:** 1R01CA248923-01A1
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** LEIF W ELLISEN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $751,170
- **Award type:** 1
- **Project period:** 2022-04-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10347682

## Citation

> US National Institutes of Health, RePORTER application 10347682, Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans (1R01CA248923-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10347682. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*